Pluristem Therapeutics Inc. (NASDAQ:PSTI)’s share price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.52 and traded as high as $3.98. Pluristem Therapeutics shares last traded at $3.83, with a volume of 3,005 shares traded.
Several analysts recently issued reports on PSTI shares. ValuEngine upgraded shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 3rd. Zacks Investment Research downgraded shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 15th. HC Wainwright restated a “buy” rating and set a $15.50 price objective on shares of Pluristem Therapeutics in a research report on Wednesday, November 13th. Maxim Group restated a “buy” rating and set a $8.00 target price on shares of Pluristem Therapeutics in a research note on Wednesday, December 4th. Finally, Dawson James began coverage on Pluristem Therapeutics in a report on Monday, December 16th. They issued a “buy” rating and a $12.00 target price on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $9.94.
The company has a quick ratio of 2.74, a current ratio of 2.74 and a debt-to-equity ratio of 0.07. The stock has a market cap of $59.86 million, a price-to-earnings ratio of -1.15 and a beta of 1.11. The company has a 50 day simple moving average of $3.89 and a 200 day simple moving average of $3.55.
Pluristem Therapeutics Company Profile (NASDAQ:PSTI)
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.